Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3945309 | Gynecologic Oncology | 2006 | 6 Pages |
Abstract
This large, multicenter phase II study of prolonged infusion topotecan in combination with cisplatin demonstrated similar response, time to progression and survival compared with reported results of taxane and platinum combinations. Hematologic toxicity was greater but tolerated. Further studies investigating topotecan in combination with platinum therapy as a first line agent are warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Howard S. Hochster, Elizabeth R. Plimack, John Mandeli, Scott Wadler, Carolyn Runowicz, Gary Goldberg, James Speyer, Robert Wallach, Franco Muggia,